Fighting diabetes, other diseases, with live cells

The promise of regenerative medicine to rebuild tissue and even organs has major implications for patients — and investors in biotech and pharma firms — if that promise holds.
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.